Skip to content
value.today

Intersect Ent: peers

Change the peers

Intersect Ent beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Intersect Ent, CeriBell, Inc., AdaptHealth Corp.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Intersect Ent, Integra LifeSciences Holdings Corporation, CeriBell, Inc., SI-BONE, Inc., AdaptHealth Corp., IRadimed Corporation, Varex Imaging Corporation, Cytek Biosciences, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureIntersect Entbase
XENT · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Integra LifeSciences Holdings Corporation
IART · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
CeriBell, Inc.
CBLL · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
SI-BONE, Inc.
SIBN · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
AdaptHealth Corp.
AHCO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
IRadimed Corporation
IRMD · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Varex Imaging Corporation
VREX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Cytek Biosciences, Inc.
CTKB · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$914 Mlast known, Jan 7, 2022 · Market dataLast known value: no current one4th of 8$921 MOct 22, 2026 · Market data3rd of 8$895 MAug 1, 2026 · Market data5th of 8$1.0 BOct 30, 2026 · Market data2nd of 8$792 MAug 1, 2026 · Market data6th of 8$1.1 BSep 25, 2026 · Market data1st of 8$778 MOct 16, 2026 · Market data7th of 8$770 MOct 27, 2026 · Market data8th of 8$905 M8 ranked
Revenue (Better neither way: ranked highest first)$107 MFY2021 · SEC6th of 8$1.6 BFY2025 · SEC2nd of 8$89 MFY2025 · SEC7th of 8$201 MFY2025 · SEC5th of 8$3.2 BFY2025 · SEC1st of 8$84 MFY2025 · SEC8th of 8$845 MFY2025 · SEC3rd of 8$201 MFY2025 · SEC4th of 8$201 M8 ranked
Net income (Higher is better)$-160 MFY2021 · SEC7th of 8$-516 MFY2025 · SEC8th of 8$-53 MFY2025 · SEC3rd of 8$-19 MFY2025 · SEC2nd of 8$-71 MFY2025 · SEC6th of 8$22 MFY2025 · SEC1st of 8$-70 MFY2025 · SEC5th of 8$-67 MFY2025 · SEC4th of 8$-68 M8 ranked
Employees (Better neither way: ranked highest first)406As on December 2020 · Profile4th of 83,800As on December 2021 · Profile2nd of 8327December 31, 2025 · Profile7th of 8357As on 2022 · Profile6th of 810,700As on 2021 · Profile1st of 8166December 31, 2025 · Profile8th of 82,100As on 2021 · Profile3rd of 8390As on March 2021 · Profile5th of 83988 ranked
Growth
Market cap change, 30 days (Higher is better)——————————————+11.1%30 days to Oct 27, 2026 · Market dataonly one with it+11.1%—
Revenue growth (Higher is better)————+1.5%FY2025 · SEC5th of 730th34th+36.1%FY2025 · SEC1st of 780th88th+20.2%FY2025 · SEC2nd of 769th79th-0.5%FY2025 · SEC7th of 725th28th+14.4%FY2025 · SEC3rd of 758th71st+4.1%FY2025 · SEC4th of 735th42nd+0.5%FY2025 · SEC6th of 727th30th+4.1%7 ranked
Revenue growth, 3 years a year (Higher is better)————+1.6%FY2025 · SEC5th of 631st39th————+23.6%FY2025 · SEC1st of 676th88th+3.0%FY2025 · SEC4th of 637th44th+16.3%FY2025 · SEC2nd of 667th81st-0.6%FY2025 · SEC6th of 626th31st+7.1%FY2025 · SEC3rd of 647th60th+5.0%6 ranked
Earnings per share growth (Higher is better)————————————————————+16.7%FY2025 · SEConly one with it59th59th————————+16.7%—
Margins and returns
Gross margin (Higher is better)————50.9%FY2025 · SEC5th of 738th65th87.9%FY2025 · SEC1st of 789th96th79.6%FY2025 · SEC2nd of 780th91st18.8%FY2025 · SEC7th of 78th18th76.8%FY2025 · SEC3rd of 777th88th34.4%FY2025 · SEC6th of 720th42nd51.8%FY2025 · SEC4th of 739th66th51.8%7 ranked
Operating margin (Higher is better)————-30.2%FY2025 · SEC6th of 738th19th-65.6%FY2025 · SEC7th of 728th13th-11.1%FY2025 · SEC4th of 747th26th2.8%FY2025 · SEC2nd of 762nd48th31.2%FY2025 · SEC1st of 795th94th-3.3%FY2025 · SEC3rd of 753rd34th-20.0%FY2025 · SEC5th of 741st22nd-11.1%7 ranked
Net margin (Higher is better)————-31.6%FY2025 · SEC5th of 737th18th-60.0%FY2025 · SEC7th of 729th13th-9.4%FY2025 · SEC4th of 748th28th-2.2%FY2025 · SEC2nd of 757th38th26.8%FY2025 · SEC1st of 792nd93rd-8.3%FY2025 · SEC3rd of 750th29th-33.0%FY2025 · SEC6th of 736th17th-9.4%7 ranked
Free cash flow margin (Higher is better)————-1.9%FY2025 · SEC4th of 749th30th-46.7%FY2025 · SEC7th of 728th12th-4.5%FY2025 · SEC6th of 745th26th6.8%FY2025 · SEC2nd of 766th60th20.5%FY2025 · SEC1st of 788th89th2.2%FY2025 · SEC3rd of 757th42nd-4.3%FY2025 · SEC5th of 745th26th-1.9%7 ranked
Return on equity (Higher is better)————-39.9%FY2025 · SEC7th of 749th21st-30.8%FY2025 · SEC6th of 753rd23rd-11.0%FY2025 · SEC3rd of 766th33rd-4.6%FY2025 · SEC2nd of 770th37th24.8%FY2025 · SEC1st of 793rd89th-14.0%FY2025 · SEC4th of 764th30th-18.1%FY2025 · SEC5th of 761st29th-14.0%7 ranked
Valuation
P/E ratio (Better neither way: ranked highest first)————70.9×price Oct 22, 2026 · Market data1st of 382nd92nd————————————45.4×price Sep 25, 2026 · Market data2nd of 368th85th35.2×price Oct 16, 2026 · Market data3rd of 356th78th————45.4×3 ranked
Price to sales (Better neither way: ranked highest first)————0.6×price Oct 22, 2026 · Market data5th of 510th17th8.2×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price4.6×price Oct 30, 2026 · Market data2nd of 555th75th0.2×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price12.2×price Sep 25, 2026 · Market data1st of 577th91st0.9×price Oct 16, 2026 · Market data4th of 515th27th3.7×price Oct 27, 2026 · Market data3rd of 550th69th3.7×5 ranked
Price to book (Better neither way: ranked highest first)————0.9×price Oct 22, 2026 · Market data5th of 516th17th5.8×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price5.7×price Oct 30, 2026 · Market data2nd of 571st79th0.5×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price11.5×price Sep 25, 2026 · Market data1st of 586th91st1.6×price Oct 16, 2026 · Market data4th of 533rd40th2.3×price Oct 27, 2026 · Market data3rd of 540th52nd2.3×5 ranked
Free cash flow yield (Higher is better)————-3.4%price Oct 22, 2026 · Market data5th of 557th29th-4.7%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price-0.9%price Oct 30, 2026 · Market data3rd of 565th35th27.7%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price1.6%price Sep 25, 2026 · Market data2nd of 574th44th2.4%price Oct 16, 2026 · Market data1st of 577th49th-1.1%price Oct 27, 2026 · Market data4th of 564th34th-0.9%5 ranked
Financial strength
Debt to equity (Lower is better)————0.7×FY2025 · SEC2nd of 464th55th————0.2×FY2025 · SEC1st of 432nd23rd1.1×FY2025 · SEC4th of 478th71st————0.8×FY2025 · SEC3rd of 468th60th————0.7×4 ranked
Net debt to EBITDA (Lower is better)————————————————3.5×FY2025 · SEConly one with it74th68th————————————3.5×—
Interest cover (Higher is better)————————————————0.9×FY2025 · SEConly one with it74th52nd————————————0.9×—
Piotroski F-score (Higher is better)——5 of 9FY2025 · SEC2nd of 4——6 of 9FY2025 · SEC1st of 44 of 9FY2025 · SEC4th of 4——5 of 9FY2025 · SEC2nd of 4——5.0 of 94 ranked
Scorecard
Scorecard (Higher is better)——8 of 24FY2025 · Scorecard4th of 73 of 9FY2025 · Scorecard4th of 710 of 24FY2025 · Scorecard3rd of 76 of 18FY2025 · Scorecard4th of 718 of 25FY2025 · Scorecard1st of 710 of 22FY2025 · Scorecard2nd of 77 of 22FY2025 · Scorecard7th of 733% passed7 ranked
Valuation checks (Higher is better)——2 of 6FY2025 · Scorecard1st of 5——0 of 5FY2025 · Scorecard4th of 5——0 of 6FY2025 · Scorecard4th of 52 of 6FY2025 · Scorecard1st of 51 of 6FY2025 · Scorecard3rd of 517% passed5 ranked
Growth checks (Higher is better)——2 of 6FY2025 · Scorecard5th of 71 of 2FY2025 · Scorecard4th of 75 of 6FY2025 · Scorecard2nd of 72 of 6FY2025 · Scorecard5th of 76 of 6FY2025 · Scorecard1st of 72 of 6FY2025 · Scorecard5th of 73 of 5FY2025 · Scorecard3rd of 750% passed7 ranked
Profitability checks (Higher is better)——0 of 5FY2025 · Scorecard5th of 70 of 3FY2025 · Scorecard5th of 71 of 5FY2025 · Scorecard2nd of 71 of 5FY2025 · Scorecard2nd of 75 of 5FY2025 · Scorecard1st of 71 of 5FY2025 · Scorecard2nd of 70 of 5FY2025 · Scorecard5th of 720% passed7 ranked
Financial health checks (Higher is better)——3 of 4FY2025 · Scorecard4th of 72 of 3FY2025 · Scorecard5th of 74 of 5FY2025 · Scorecard3rd of 72 of 6FY2025 · Scorecard7th of 73 of 3FY2025 · Scorecard1st of 74 of 4FY2025 · Scorecard1st of 72 of 3FY2025 · Scorecard5th of 775% passed7 ranked
Shareholder returns checks (Higher is better)——1 of 3FY2025 · Scorecard4th of 70 of 1FY2025 · Scorecard6th of 70 of 3FY2025 · Scorecard6th of 71 of 1FY2025 · Scorecard1st of 74 of 5FY2025 · Scorecard3rd of 71 of 1FY2025 · Scorecard1st of 71 of 3FY2025 · Scorecard4th of 733% passed7 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)——95.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 781.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7107.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7104.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 761.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 792.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 766.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 792.5%7 ranked
Institutions holding (Better neither way: ranked highest first)——2342026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 71332026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 71792026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 72482026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 72152026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 71802026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 71522026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 71807 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)——-1.7 pp2026-Q2 against 2026-Q1 · 13F5th of 7+0.8 pp2026-Q2 against 2026-Q1 · 13F3rd of 7+9.7 pp2026-Q2 against 2026-Q1 · 13F1st of 7-0.1 pp2026-Q2 against 2026-Q1 · 13F4th of 7+1.8 pp2026-Q2 against 2026-Q1 · 13F2nd of 7-2.0 pp2026-Q2 against 2026-Q1 · 13F6th of 7-3.1 pp2026-Q2 against 2026-Q1 · 13F7th of 7-0.1 pp7 ranked
Dividends
Dividend yield (Higher is better)————————————————————1.4%FY2025 · SEConly one with it63rd35th————————1.4%—
Shareholder yield (Higher is better)————0.0%FY2025 · SEC3rd of 314th6th————————0.0%FY2025 · SECnot ranked: old priceold priceold price1.4%FY2025 · SEC2nd of 339th26th————2.0%FY2025 · SEC1st of 348th34th1.4%3 ranked
Dividend payout (Better neither way: ranked highest first)————————————————————66.9%FY2025 · SEConly one with it84th74th————————66.9%—
Dividend per share (Better neither way: ranked highest first)——————$0.00FY2025 · SEConly one with it————————$0.00—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Intersect Ent: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Integra LifeSciences Holdings Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; CeriBell, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; SI-BONE, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; AdaptHealth Corp.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; IRadimed Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Varex Imaging Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Cytek Biosciences, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Intersect Ent———
Integra LifeSciences Holdings Corporation-30.2%FY2025
38th percentile in Healthcaremedian -7.7%, 674 companies
19th percentile in USAmedian 3.5%, 2,594 companies
CeriBell, Inc.-65.6%FY2025
28th percentile in Healthcaremedian -7.7%, 674 companies
13th percentile in USAmedian 3.5%, 2,594 companies
SI-BONE, Inc.-11.1%FY2025
47th percentile in Healthcaremedian -7.7%, 674 companies
26th percentile in USAmedian 3.5%, 2,594 companies
AdaptHealth Corp.2.8%FY2025
62nd percentile in Healthcaremedian -7.7%, 674 companies
48th percentile in USAmedian 3.5%, 2,594 companies
IRadimed Corporation31.2%FY2025
95th percentile in Healthcaremedian -7.7%, 674 companies
94th percentile in USAmedian 3.5%, 2,594 companies
Varex Imaging Corporation-3.3%FY2025
53rd percentile in Healthcaremedian -7.7%, 674 companies
34th percentile in USAmedian 3.5%, 2,594 companies
Cytek Biosciences, Inc.-20.0%FY2025
41st percentile in Healthcaremedian -7.7%, 674 companies
22nd percentile in USAmedian 3.5%, 2,594 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$815 M$1.6 B$2.4 B$3.3 B20102012201420162018202020222024Intersect Ent $107 MIntegra LifeSciences Holdings Corporation $1.6 BCeriBell, Inc. $89 MSI-BONE, Inc. $201 MAdaptHealth Corp. $3.2 BIRadimed Corporation $84 MVarex Imaging Corporation $845 MCytek Biosciences, Inc. $201 M

Rank in the group

1st2nd3rd4th5th6th7th20122013201420152016201720182019202020212022202320242025Intersect Ent: 2nd of 2 in 2012Intersect Ent: 2nd of 3 in 2013Intersect Ent: 2nd of 3 in 2014Intersect Ent: 3rd of 4 in 2015Intersect Ent: 3rd of 4 in 2016Intersect Ent: 3rd of 5 in 2017Intersect Ent: 4th of 6 in 2018Intersect Ent: 4th of 6 in 2019Intersect Ent: 5th of 7 in 2020Intersect Ent: 5th of 7 in 2021Intersect EntIntegra LifeSciences Holdings Corporation: 1st of 2 in 2012Integra LifeSciences Holdings Corporation: 1st of 3 in 2013Integra LifeSciences Holdings Corporation: 1st of 3 in 2014Integra LifeSciences Holdings Corporation: 1st of 4 in 2015Integra LifeSciences Holdings Corporation: 1st of 4 in 2016Integra LifeSciences Holdings Corporation: 1st of 5 in 2017Integra LifeSciences Holdings Corporation: 1st of 6 in 2018Integra LifeSciences Holdings Corporation: 1st of 6 in 2019Integra LifeSciences Holdings Corporation: 1st of 7 in 2020Integra LifeSciences Holdings Corporation: 2nd of 7 in 2021Integra LifeSciences Holdings Corporation: 2nd of 6 in 2022Integra LifeSciences Holdings Corporation: 2nd of 7 in 2023Integra LifeSciences Holdings Corporation: 2nd of 7 in 2024Integra LifeSciences Holdings Corporation: 2nd of 7 in 2025Integra LifeSciences HoldiCeriBell, Inc.: 7th of 7 in 2023CeriBell, Inc.: 7th of 7 in 2024CeriBell, Inc.: 6th of 7 in 2025CeriBell, Inc.SI-BONE, Inc.: 4th of 5 in 2017SI-BONE, Inc.: 5th of 6 in 2018SI-BONE, Inc.: 5th of 6 in 2019SI-BONE, Inc.: 6th of 7 in 2020SI-BONE, Inc.: 6th of 7 in 2021SI-BONE, Inc.: 5th of 6 in 2022SI-BONE, Inc.: 5th of 7 in 2023SI-BONE, Inc.: 5th of 7 in 2024SI-BONE, Inc.: 5th of 7 in 2025SI-BONE, Inc.AdaptHealth Corp.: 3rd of 6 in 2018AdaptHealth Corp.: 3rd of 6 in 2019AdaptHealth Corp.: 2nd of 7 in 2020AdaptHealth Corp.: 1st of 7 in 2021AdaptHealth Corp.: 1st of 6 in 2022AdaptHealth Corp.: 1st of 7 in 2023AdaptHealth Corp.: 1st of 7 in 2024AdaptHealth Corp.: 1st of 7 in 2025AdaptHealth Corp.IRadimed Corporation: 3rd of 3 in 2013IRadimed Corporation: 3rd of 3 in 2014IRadimed Corporation: 4th of 4 in 2015IRadimed Corporation: 4th of 4 in 2016IRadimed Corporation: 5th of 5 in 2017IRadimed Corporation: 6th of 6 in 2018IRadimed Corporation: 6th of 6 in 2019IRadimed Corporation: 7th of 7 in 2020IRadimed Corporation: 7th of 7 in 2021IRadimed Corporation: 6th of 6 in 2022IRadimed Corporation: 6th of 7 in 2023IRadimed Corporation: 6th of 7 in 2024IRadimed Corporation: 7th of 7 in 2025IRadimed CorporationVarex Imaging Corporation: 2nd of 4 in 2015Varex Imaging Corporation: 2nd of 4 in 2016Varex Imaging Corporation: 2nd of 5 in 2017Varex Imaging Corporation: 2nd of 6 in 2018Varex Imaging Corporation: 2nd of 6 in 2019Varex Imaging Corporation: 3rd of 7 in 2020Varex Imaging Corporation: 3rd of 7 in 2021Varex Imaging Corporation: 3rd of 6 in 2022Varex Imaging Corporation: 3rd of 7 in 2023Varex Imaging Corporation: 3rd of 7 in 2024Varex Imaging Corporation: 3rd of 7 in 2025Varex Imaging CorporationCytek Biosciences, Inc.: 4th of 7 in 2020Cytek Biosciences, Inc.: 4th of 7 in 2021Cytek Biosciences, Inc.: 4th of 6 in 2022Cytek Biosciences, Inc.: 4th of 7 in 2023Cytek Biosciences, Inc.: 4th of 7 in 2024Cytek Biosciences, Inc.: 4th of 7 in 2025Cytek Biosciences, Inc.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearIntersect EntIntegra LifeSciences Holdings CorporationCeriBell, Inc.SI-BONE, Inc.AdaptHealth Corp.IRadimed CorporationVarex Imaging CorporationCytek Biosciences, Inc.
2025—$1.6 BSEC2nd$89 MSEC6th$201 MSEC5th$3.2 BSEC1st$84 MSEC7th$845 MSEC3rd$201 MSEC4th
2024—$1.6 BSEC2nd$65 MSEC7th$167 MSEC5th$3.3 BSEC1st$73 MSEC6th$811 MSEC3rd$200 MSEC4th
2023—$1.5 BSEC2nd$45 MSEC7th$139 MSEC5th$3.2 BSEC1st$66 MSEC6th$893 MSEC3rd$193 MSEC4th
2022—$1.6 BSEC2nd—$106 MSEC5th$3.0 BSEC1st$53 MSEC6th$859 MSEC3rd$164 MSEC4th
2021$107 MSEC5th$1.5 BSEC2nd—$90 MSEC6th$2.5 BSEC1st$42 MSEC7th$818 MSEC3rd$128 MSEC4th
2020$81 MSEC5th$1.4 BSEC1st—$73 MSEC6th$1.1 BSEC2nd$32 MSEC7th$738 MSEC3rd$93 MSEC4th
2019$109 MSEC4th$1.5 BSEC1st—$67 MSEC5th$530 MSEC3rd$39 MSEC6th$781 MSEC2nd—
2018$108 MSEC4th$1.5 BSEC1st—$55 MSEC5th$345 MSEC3rd$30 MSEC6th$773 MSEC2nd—
2017$96 MSEC3rd$1.2 BSEC1st—$48 MSEC4th—$23 MSEC5th$698 MSEC2nd—
2016$79 MSEC3rd$992 MSEC1st———$33 MSEC4th$620 MSEC2nd—
2015$62 MSEC3rd$883 MSEC1st———$32 MSEC4th$632 MSEC2nd—
2014$39 MSEC2nd$797 MSEC1st———$16 MSEC3rd——

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Intersect Ent#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Integra LifeSciences Holdings CorporationIART · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $921 M market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $921 M (Oct 22, 2026) · revenue $1.6 B (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • CeriBell, Inc.CBLL · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $895 M market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $895 M (Aug 1, 2026) · revenue $89 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • SI-BONE, Inc.SIBN · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $1.0 B market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $1.0 B (Oct 30, 2026) · revenue $201 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • AdaptHealth Corp.AHCO · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $792 M market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $792 M (Aug 1, 2026) · revenue $3.2 B (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • IRadimed CorporationIRMD · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $1.1 B market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $1.1 B (Sep 25, 2026) · revenue $84 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • Varex Imaging CorporationVREX · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $778 M market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $778 M (Oct 16, 2026) · revenue $845 M (year to October 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • Cytek Biosciences, Inc.CTKB · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $770 M market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $770 M (Oct 27, 2026) · revenue $201 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • Artivion, Inc.AORT · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $739 M market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $739 M (Oct 30, 2026) · revenue $441 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • Avanos Medical, Inc.AVNS · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $1.2 B market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $1.2 B (last known, Aug 1, 2026) · revenue $701 M (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    + Add
  • MiMedx Group, Inc.MDXG · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $684 M market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $684 M (Oct 14, 2026) · revenue $419 M (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    + Add
  • CONMED CorporationCNMD · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $1.4 B market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $1.4 B (Oct 14, 2026) · revenue $1.4 B (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    + Add
  • Tandem Diabetes Care, Inc.TNDM · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $1.4 B market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $1.4 B (Oct 30, 2026) · revenue $1.0 B (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.